health-policy12.755 min read
States rely on consultants to enforce Trump-era Medicaid work rules
12 days ago•Source: CBS News
Health Policy News
The latest health policy stories, summarized by AI
Featured Health Policy Stories
View original source
11.87 min•19 days ago
Kennedy eyes FDA action to widen peptide access and spur a booming market
Health Secretary Kennedy Jr. signals that the FDA will broaden access to peptide therapies—a fast-growing, largely unregulated market—by taking action that could loosen rules for domestic compounding. Supporters say it will improve patient access, while critics warn of safety risks due to limited long-term data and a thriving gray/black market for unproven products. The move comes amid industry litigation, lobbying by compounding pharmacies, and high commercial interest in peptide-based treatments like GLP-1 therapies.
More Top Stories
2
3
Urgent Push for a National Covid Vaccine Injury Tracking Network
The New York Times•26 days ago
More Health Policy Stories
States Rally Behind Trump-Era Health Credits to Boost ACA Sign-Ups
Across red and blue states, lawmakers are embracing the Trump-era rule that lets employers offer tax-exempt credits to workers to buy ACA plans through Individual Coverage Health Reimbursement Arrangements (ICHRA), a strategy aimed at tamping down uninsured rates after enhanced ACA subsidies expired. With six states weighing bills and insurers like Oscar Health supporting the approach, ICHRAs have bipartisan appeal, but they’re not a universal cure and may not always outperform traditional subsidies or employer plans depending on income and coverage choices.
Still Fighting for Coverage: The Unfinished Battle Over Medical Preauthorization
Despite insurance pledges to simplify preauthorization, patients still face frequent denials and costly delays for necessary care. The piece follows Sheldon Ekirch and other patients who endured years of fights over IVIG and other treatments, including a successful reversal of a denial that required huge personal expenses, while COBRA transitions loom. Insurers tout changes like bundling and removing some approvals, but clinicians, patients, and experts question whether reforms will meaningfully improve access, a concern echoed by a 39% share of chronic-patient respondents in a KFF poll.
FDA keeps leucovorin for a rare condition, not autism
The FDA said leucovorin will be approved only for cerebral folate deficiency (CFD-FOLR1) and will not be expanded to autism, despite the Trump administration’s push. Regulators cited limited evidence for autism treatment and noted a retraction of a key study, narrowing the review to the rare CFD-FOLR1 condition and highlighting the gap between political claims and scientific proof for autism therapies.
FDA advisory panels retreat from public scrutiny as controversial drug decisions mount
Advisory panels are playing a smaller public role as drug regulatory decisions grow more contentious, with a Trump-era private briefing in which an FDA official anonymously criticized UniQure’s Huntington’s disease therapy illustrating a shift toward nonpublic decision-making and sparking calls for greater transparency from patients and clinicians.
Controversial FDA Vaccine Chief to Resign
Dr. Vinay Prasad, a divisive FDA vaccine regulator who overruled career scientists and pressed a crackdown on a biotech firm, is resigning at the end of April after a turbulent tenure that included a brief dismissal sparked by Laura Loomer’s attack and a later reinstatement urged by FDA Commissioner Marty Makary and Health Secretary Robert F. Kennedy Jr.
The price tag on the FDA’s aggressive regulatory push
An opinion piece argues that FDA leaders Peter Marks and Vinay Prasad have pursued a rigorous, aggressive regulatory approach that comes with costs for biotech firms and patients, fueling debate over approving drugs with uncertain benefits.
Budget Strains Push States to Trim HIV Drug Access Under Ryan White
Budget pressures are pushing states to tighten enrollment and services in ADAPs funded by the Ryan White program, with Florida restricting income eligibility and removing Biktarvy from its formulary. Across 23 states, cost-containment measures are being implemented or considered as ADAP funding lags inflation, drug prices rise, and the expiration of enhanced ACA premium tax credits drives up insurance costs—threatening access to HIV treatment and potentially worsening health outcomes and transmission.
Birth control access under scrutiny as surgeon general pick defends options
The article reports that the Trump administration’s surgeon general nominee faced questions about her past remarks on birth control but reiterated support for access for all women, emphasizing that patients should discuss risks with their doctors. It notes hormonal contraception is widely used for pregnancy prevention and other health reasons, with mostly mild side effects. While meta-analyses show a small, very low increase in breast cancer risk, overall cancer risk remains low and some data suggest protective effects for other cancers. Experts urge maintaining all contraceptive options and caution against inflammatory rhetoric that could limit informed choices.
FDA Unveils Plausible Mechanism Framework to Accelerate Tailored Therapies for Ultra-Rare Diseases
The FDA issued a draft guidance outlining a Plausible Mechanism Framework to accelerate approvals of genome-editing and RNA-based, individualized therapies that target the root causes of ultra-rare diseases, allowing smaller, robust studies and the use of master protocols. Sponsors must demonstrate the therapy addresses the specific disease mechanism, rely on well-characterized natural history data, and show target engagement or editing; public comments are due within 60 days.
FDA chief vows tighter safety review of antidepressants in pregnancy and RSV protections for infants
In her first staff address, FDA’s top drug regulator Tracy Beth Høeg pledges tougher safety monitoring of antidepressants used in pregnancy and RSV monoclonal antibodies for infants, signaling a broader push to reexamine oversight and encouraging staff to question norms.